# NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
> **ANDA211360** · Abbreviated New Drug Application (Generic) · Sponsor: AUROBINDO PHARMA · Approved 2022-06-01
## Drug
- **FDA Application Number:** ANDA211360
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
- **Generic name:** NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE
- **Active ingredients:** NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE
- **Dosage form:** TABLET, EXTENDED RELEASE
- **Route:** ORAL
- **Marketing status:** Over-the-counter
- **Sponsor:** AUROBINDO PHARMA
- **Manufacturer:** VESPYR BRANDS LLC
- **First approval:** 2022-06-01
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211360)
---
*AI Analytics · CC0 1.0*